PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study examines reasons for delay, denial of new drugs by FDA

2014-01-22
(Press-News.org) Contact information: Sandy Walsh
sandy.walsh@fda.hhs.gov
301-796-4669
The JAMA Network Journals
Study examines reasons for delay, denial of new drugs by FDA Several potentially preventable deficiencies, including failure to select optimal drug doses and suitable outcome measures for a study, accounted for significant delays in the approval of new drugs by the Food and Drug Administration (FDA), according to a study in the January 22/29 issue of JAMA.

"The road from medical product discovery to marketing is typically long and costly. The interval between initial clinical testing and product approval has been estimated to average 8 years and only 1 in 6 drugs entering clinical trials ultimately obtains U.S. Food and Drug Administration approval," according to background information in the article. Many drugs do not receive approval not because they are unsafe or ineffective, but because the information supplied is unsatisfactory to make that determination. Delays and failures that occur late in development affect the availability of innovative new drugs and increase the costs of drug development.

Leonard V. Sacks, M.B.B.Ch., of the U.S. Food and Drug Administration, Silver Spring, Md., and colleagues reviewed marketing applications for all new molecular entities (NMEs; active ingredients never before marketed in the United States in any form) first submitted to the FDA between 2000 and 2012. Using FDA correspondence and reviews, the researchers investigated the scientific and regulatory reasons approval of NMEs were delayed or denied.

Of the 302 identified NME applications, 151 (50 percent) were approved when first submitted and 222 (73.5 percent) eventually achieved marketing approval. Of the 151 first-cycle failures, 71 (47.0 percent) eventually obtained approval in a median (midpoint) of 435 days following the first unsuccessful submission.

Among the reasons for failure to initially receive approval: Uncertainty about the optimal dose to maximize efficacy and to minimize safety risks; Populations that were studied did not reflect the populations likely to use the drug; End points used in clinical trials were unsatisfactory; Inconsistent results for multiple predefined end points in clinical studies; Inconsistencies in efficacy for portions of the study population.

There were 20 drugs (13.2 percent) that despite showing superiority to placebo were considered to have inadequate efficacy compared with the standard of care.

The frequency of safety deficiencies was similar among never-approved drugs compared with those with delayed approval. However, efficacy deficiencies were significantly more frequent among the never-approved drugs than among those with delayed approvals. Among the 48 drugs with initial efficacy concerns alone, only 31.3 percent were eventually approved compared with 61.5 percent of the 39 drugs with safety concerns alone.

"Failures late in drug development are costly, often involving the commitment of many study participants and personnel. It is advantageous to identify products that fail as early as possible in the development process to avoid these issues. For those drugs that require resubmission before approval is obtained, delays are taxing on the industry and regulators, and patients may have to wait for access to promising, and sometimes lifesaving, new treatments," the authors write.

"Our findings may be helpful to clinicians and policy makers in interpreting the extensive literature reporting the design and outcome of clinical trials, which in turn may have an effect on practice. For drug developers and clinical investigators, our findings suggest areas of deficiencies in new drug applications in which strategies for drug development could be improved. Early and frequent dialogue between the FDA and drug sponsors addressing critical aspects of study design (including the selection of study populations, study end points, and drug doses) has the potential to reduce delays in the approval of new drugs." ### (doi:10.1001/jama.2013.282542; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.


ELSE PRESS RELEASES FROM THIS DATE:

Biomarkers in blood show potential as early detection method of pancreatic cancer

2014-01-22
Biomarkers in blood show potential as early detection method of pancreatic cancer Researchers have identified diagnostic microRNA panels in whole blood that had the ability to distinguish, to some degree, patients with and without pancreatic cancer, according ...

Many CV devices approved by process that often does not require new clinical data

2014-01-22
Many CV devices approved by process that often does not require new clinical data Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective ...

Mediterranean diet associated with lower risk of peripheral artery disease

2014-01-22
Mediterranean diet associated with lower risk of peripheral artery disease A multicenter study that previously reported a reduction in heart attack and stroke with a Mediterranean diet supplemented with extra-virgin olive oil or with nuts now also reports a ...

Deaths higher for heart attack patients at night and weekends

2014-01-22
Deaths higher for heart attack patients at night and weekends Research: Off-hour presentation and outcomes in patients with acute myocardial infarction: systematic review and meta-analysis Mortality is higher, and emergency treatment takes longer, for ...

Long term exposure to air pollution linked to coronary events

2014-01-22
Long term exposure to air pollution linked to coronary events Association persists at levels of exposure below current European limits Long term exposure to particulate matter in outdoor air is strongly linked to heart attacks and angina, and this association ...

Losing a family member in childhood associated with psychotic illness

2014-01-22
Losing a family member in childhood associated with psychotic illness Highest risk seen in children who experience suicide in close family members Experiencing a family death in childhood is associated with a small but significant increase in risk of psychosis, ...

Fast eye movements: A possible indicator of more impulsive decision-making

2014-01-22
Fast eye movements: A possible indicator of more impulsive decision-making Using a simple study of eye movements, Johns Hopkins scientists report evidence that people who are less patient tend to move their eyes with greater speed. The findings, the researchers say, ...

Most high-risk cardiac devices in use today approved as modifications to previously-approved devices

2014-01-22
Most high-risk cardiac devices in use today approved as modifications to previously-approved devices Device 'supplement' applications are generally not accompanied by new clinical testing, with implications for patient safety Boston – The Food and Drug Administration ...

New sequencing tools give up close look at yeast evolution

2014-01-22
New sequencing tools give up close look at yeast evolution Highlights in this week's Molecular Biology and Evolution The baker's yeast Saccharomyces cerevisiae has been associated with human activities for thousands of ...

All FDA drug approvals not created equal

2014-01-22
All FDA drug approvals not created equal Many patients and physicians assume that the safety and effectiveness of newly approved drugs is well understood by the federal Food and Drug Administration (FDA) —but a new study by researchers at Yale School of Medicine shows ...

LAST 30 PRESS RELEASES:

Boston University professor to receive 2025 Eugene Braunwald Academic Mentorship Award

Pusan National University researchers reveal how forest soil properties influence arsenic mobility and toxicity in soil organisms

Korea University researchers find sweet taste cells resist nerve damage through c-Kit protein

HealthFORCE, AAPA, and West Health release “Aging Well with AI” – first in a two part series on AI and the healthcare workforce

The real reasons Endurance sank — study finds Shackleton knew of ship’s shortcomings

Marine heatwaves have hidden impacts on ocean food webs and carbon cycling

Order from disordered proteins

Rocket test proves bacteria survive space launch and re-entry unharmed

New wheat diversity discovery could provide an urgently-needed solution to global food security

Could reducing inflammation help combat fatigue in people with early-stage breast cancer?

Traumatic brain injuries in older adults linked to increased risk of dementia

New intervention helps pediatricians promote early peanut introduction to prevent peanut allergy

New survey: Most Americans believe plasma donation saves lives, yet few have donated

New tools boost pediatricians’ adherence to peanut allergy guidelines 15-fold

Research unearths origins of Ancient Egypt’s Karnak Temple

Reevaluating nonoperative management for pediatric uncomplicated acute appendicitis

Metabolically active visceral fat linked to aggressive endometrial cancer, new study reveals

Scientists glimpse how enzymes “dance” while they work, and why that’s important

California partnership aided COVID-19 response and health equity, report finds

University of Oklahoma secures $19.9 million for revolutionary radar technology

Study finds restoring order to dividing cancer cells may prevent metastasis

High-accuracy tumor detection with label-free microscopy and neural networks

Wayne State research reveals fetuses exposed to Zika virus have long-term immune challenges

Researchers deconstruct chikungunya outbreaks to improve prediction and vaccine development

Study finds one-year change on CT scans linked to future outcomes in fibrotic lung disease

Discovery of a novel intracellular trafficking pathway in plant cells

New tool helps forecast volcano slope collapses and tsunamis

Molecular coating cleans up noisy quantum light

From Parkinson's to rare diseases, discovered a key switch for cellular health

Tiny sugars in the brain disrupt emotional circuits, fueling depression

[Press-News.org] Study examines reasons for delay, denial of new drugs by FDA